Med-X

Med-X

Growth Stage

Making a Difference, Naturally.

Making a Difference, Naturally.

Overview

Raised to Date: Raised: $3,936,422

Total Commitments ($USD)

Platform

Dalmore Group

Start Date

07/22/2021

Close Date

Not Provided

Min. Goal
$420
Max. Goal
$10,000,000
Min. Investment

$420

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$0.80

Pre-Money Valuation

$102,217,405

Rolling Commitments ($USD)

Status
Funded
Reporting Date

11/29/2023

% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$4,692

# of Investors

1,441

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2014

Industry

Consumer Products, Goods & Services

Tech Sector

Cleantech

Distribution Model

B2B2C

Margin

Medium

Capital Intensity

High

Location

Canoga Park, California

Business Type

Growth

Med-X, with a pre-money valuation of $102 million, is raising funds on Dalmore via Regulation A+. The company has developed many all-natural and plant-based brands that are replacing chemicals to solve everyday issues. The products are sold through major retail and healthcare distributors. The flagship product lines of Med-X include Nature-Cide and Thermal-Aid. Med-X is led by Dr. David Toomey and Matthew Mills and was founded in 2014.

Balance Sheet

Cash and Cash Equivalents

$752,823

Investment Securities

$0

Accounts and Notes Receivable

$150,929

Property, Plant and Equipment (PP&E)

$81,971

Total Assets

$3,081,150

Accounts Payable & Accrued Liabilities

$352,317

Long Term Debt

$1,156,573

Total Liabilities

$2,194,674

Total Stockholders' Equity

$886,476

Total Liabilities and Equity

$3,081,150

Statement of Comprehensive Income Information

Total Revenues

$1,033,750

Costs & Expenses Applicable to Rev

$711,820

Depreciation and Amortization

$115,398

Net Income

$-3,050,009

Earnings Per Share - Basic

$-0.03

Earnings Per Share - Diluted

$-0.03

Auditor: Prager Metis, CPA's LLP
Financials as of: 07/22/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Med-X 11/08/2023 Dalmore Group $102,217,405 $3,936,422 Equity - Common Funded RegA+
Med-X 05/22/2023 PicMii $43,211,544 $0 Equity - Common Not Funded RegCF
Med-X 09/09/2021 truCrowd $88,552,772 $15,595 Equity - Common Funded RegCF
Med-X 06/26/2019 StartEngine - $7,000,471 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Med-X on Dalmore Group 2021
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $102,217,405
Price per Share: $0.80

Follow company

Follow Med-X on Dalmore Group 2021

Buy Med-X's Deal Report

Warning: according to the close date for this deal, Med-X may no longer be accepting investments.

Med-X Deal Report

Get KingsCrowd’s comprehensive report on Med-X including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Med-X is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Med-X deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge